Page 21 - Gene Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Research team from Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam. view more  Credit: AlphaMed Press Durham, NC -- Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in STEM CELLS Translational Medicine. In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic v...

Study: Some Type 2 diabetes patients can benefit from bone marrow stem cell transplants Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in STEM CELLS Translational Medicine. In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabe...

ISAAA and partners present the webinar International Trade in Crops with New Breeding Technologies: The Australian Perspective to provide an insight into the future landscape of trade involving gene-edited crops, particularly in relation to countries involved in the international trade of agricultural products. It will be held on June 11, 2021, at 2 PM GMT+8 (4 PM Sydney) via Zoom.

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand The leading Australian CRO Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. BriefingWire.com, 5/09/2021 - ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet th...

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR). This accreditation recognizes that Avance Clinical has the CRO resources and ...